<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974424</url>
  </required_header>
  <id_info>
    <org_study_id>S160</org_study_id>
    <nct_id>NCT04974424</nct_id>
  </id_info>
  <brief_title>Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV</brief_title>
  <official_title>Study on Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Women's Hospital School Of Medicine Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Obstetrics &amp; Gynecology Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most uterine cervical high-risk human papillomavirus (HPV) infections are transient, with&#xD;
      only a small fraction developing into cervical cancer. Family aggregation studies and&#xD;
      heritability estimates suggest a significant inherited genetic component. Candidate gene&#xD;
      studies and previous genome-wide association studies (GWASs) report associations between the&#xD;
      HLA region and cervical cancer. Adopting a genome-wide approach, we aimed to establish an&#xD;
      early warning model for a high-risk population of cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Significant loci of genetic variation</measure>
    <time_frame>2</time_frame>
    <description>The impact of genetic variance on predisposition to cervical cancer</description>
  </primary_outcome>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Uterine Cervical Neoplasm</condition>
  <condition>Uterine Cervical Cancer</condition>
  <condition>Cervical Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Case group a) Aged 25-75 years. b) Han nationality. c) Patients with cervical&#xD;
             cancer or cervical precancerous lesions above CIN2 diagnosed by biopsy or&#xD;
             postoperative pathological diagnosis.&#xD;
&#xD;
          -  (2) Control group: a) Aged 25-75 years. b) Han nationality. c) No family history of&#xD;
             cervical cancer or precancerous lesions. d) The results of TCT examination showed no&#xD;
             abnormality.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) suffering from other neoplastic diseases.&#xD;
&#xD;
          -  (2) pregnant women.&#xD;
&#xD;
          -  (3) those with a history of bone marrow transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ding Ma, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ding Ma, MD, PhD</last_name>
    <phone>0086-27-836268</phone>
    <email>dma@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ding Ma, MD</last_name>
      <phone>0086-27-8362681</phone>
      <email>dma@tjh.tjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Director of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

